Search research articles
Contact Us
Filters
Showing results (221-230 of 245) with videos related to
Page
of 25
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
February 19, 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study
M Wislez, C Mascaux, J Cadranel, et al.
ESMO Open
|
December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
O Molinier, B Besse, F Barlesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
C Leduc, J P Merlio, B Besse, et al.
Respiratory Medicine and Research
|
May 17, 2020
Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study
C Fontaine-Delaruelle, J Mazières, J Cadranel, et al.
ESMO Open
|
March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
N Girard, S Galland-Girodet, V Avrillon, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
H Blons, J-B Oudart, J-P Merlio, et al.
Respiratory Medicine and Research
|
May 23, 2021
Daily multidisciplinary COVID-19 meeting: Experiences from a French university hospital
C Rolland-Debord, A Canellas, P Choinier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
G R Blumenschein, E F Smit, D Planchard, et al.
The European Respiratory Journal
|
July 9, 2011
Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations
T Berghmans, F Pasleau, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAF<sup>V600</sup> and BRAF<sup>nonV600</sup> mutations
J Mazieres, C Cropet, L Montané, et al.
Page
of 25
Search research articles
Search
Showing results (221-230 of 245) with videos related to
Sort By:
Page
of 25
European Journal of Cancer (Oxford, England : 1990)
|
February 19, 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study
M Wislez, C Mascaux, J Cadranel, et al.
ESMO Open
|
December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
O Molinier, B Besse, F Barlesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
C Leduc, J P Merlio, B Besse, et al.
Respiratory Medicine and Research
|
May 17, 2020
Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study
C Fontaine-Delaruelle, J Mazières, J Cadranel, et al.
ESMO Open
|
March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
N Girard, S Galland-Girodet, V Avrillon, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
H Blons, J-B Oudart, J-P Merlio, et al.
Respiratory Medicine and Research
|
May 23, 2021
Daily multidisciplinary COVID-19 meeting: Experiences from a French university hospital
C Rolland-Debord, A Canellas, P Choinier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
G R Blumenschein, E F Smit, D Planchard, et al.
The European Respiratory Journal
|
July 9, 2011
Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations
T Berghmans, F Pasleau, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAF<sup>V600</sup> and BRAF<sup>nonV600</sup> mutations
J Mazieres, C Cropet, L Montané, et al.
Page
of 25